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Lassa fever, a zoonotic viral infection, is endemic in West Africa. The disease causes annual wide spread morbidity and 
mortality in Africa, and can be imported by travelers. Possible importation of Lassa fever and the potential for the use 
of Lassa virus as an agent of bioterrorism mandate clinicians in Israel and other countries to be vigilant and familiar 
with the basic characteristics of this disease. The article reviews the basis of this infection and the clinical manage‑
ment of patients with Lassa fever. Special emphasis is given to antiviral treatment and infection control.
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Background
Lassa fever (LF), or Lassa hemorrhagic fever, is an infec-
tion caused by Lassa virus (LASV). This fairly common 
disease, endemic to West Africa, is associated with sig-
nificant morbidity and mortality in some cases, and is 
contagious. Hospitalized patients with LF may pose a 
substantial risk to healthcare workers (HCWs) and to 
other patients. The recent major outbreak of Ebola virus 
disease (EVD) in West Africa, together with a few cases 
of EVD importations to countries outside Africa [1–5] 
and nosocomial transmission to HCWs [2, 6], raised the 
vigilance of western nations for EVD and similar conta-
gious infections [7]. In the meanwhile, a few large scale 
outbreaks of LF were simultaneously reported from 
Nigeria since August 2015, with a cumulative suspected 
case count of 159 as of January 2016 [8]. International 
transportation to and from Africa increased dramatically 
in the last decade, further increasing the risk for infec-
tious disease exportation from endemic areas [9]. Unlike 
the rare outbreaks of EVD, LF cases in Africa are com-
mon and occur annually, therefor posing a continuous 
theoretical threat to travelers. Thus, local physicians in 
Israel and in other countries outside Africa should be 
familiar with LF as a possible diagnosis in travelers. The 
article will review the updated data about LF epidemiol-
ogy, pathogenesis and clinical management.
Methods
A Pubmed search for medical literature was carried 
out using the terms “Lassa fever” and “Lassa virus”, and 
“Lassa” together with the terms “Travelers”, “Importa-
tion”, “Healthcare workers”, “Laboratory acquired infec-
tion”. Additional data was retrieved from the World 
Health Organization (WHO) and Centers for Disease 
Control and Prevention (CDC) websites. Relevant publi-
cations were reviewed and are presented herein.
Virology
LASV is a single-stranded RNA virus, belonging to the 
arenaviruses (AV) family. All members of this family 
are composed of two segments of ambisense RNA and a 
nucleoprotein (NP), surrounded by a lipid envelope and a 
glycoprotein (GP). Electronic microscopy shows charac-
teristic grainy particles inside the virus, traced to be host 
ribosomes, which give it its name (Arena = sandy).
The AV are classified according to their geographic dis-
tribution. The old world AV include the world-wide leu-
kocytic choriomeningitis virus (LCMV), and the African 
LASV, Lujo virus, and a few other viruses, not known to 
be pathogenic to humans. The new world AV is distrib-
uted in specific areas in the American continents, and 
includes the pathogenic Junin, Guanarito, Machupo, and 
Sabia viruses and other non-pathogenic species [10].
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Epidemiology
The AV are sustained in nature in chronically infected 
rodents. The natural host of LASV is Mastomyces natal-
ensis, the most common rat in rural West Africa, com-
monly found in households. The virus is shed in the rat’s 
urine, feces, and respiratory secretions and is found in 
blood. Humans get infected by direct contact with the 
rat’s excretions, by inhaling dust contaminated with 
it, or by eating the rat [11, 12]. Person to person trans-
mission occurs by direct contact, and there is very little 
epidemiological support for significant airborne trans-
mission [13, 14]. Contagiousness begins with symptom 
onset and increases with disease severity, consistent with 
the appearance of pharyngeal shedding, vomiting, diar-
rhea and bleeding, and increasing levels of viral load in 
body fluids [15–17]. The virus is shed in the urine for 
3–6  weeks, and up to 3  months in semen, with risk for 
sexual transmission, prompting condom use in survi-
vors [11, 12, 14, 18]. Cumulative experience in the west-
ern world, with more than 25 imported cases and more 
than 1500 potential contacts, showed a very limited risk 
of transmission, with only one suspected asymptomatic 
infection [16].
The disease is endemic in Nigeria, Liberia and Sierra 
Leone, with seroprevalence rates of 7  % to more than 
20  % [10, 13]. Proven cases or seropositivity were also 
reported in Cote d’Ivoire, Guinea, Central African 
Republic, Mali, Senegal and Congo [18]. The annual 
incidence is estimated as 100,000–300,000 cases, out of 
which 5000 are fatal [12]. These regions are also endemic 
to other hemorrhagic fever viruses, including Ebola, and 
indeed an outbreak of LF occurred in Liberia during 
2014, as the activity of EVD was high, complicating the 
differential diagnosis of suspected cases [19]. As the incu-
bation period can be fairly long, and the clinical presenta-
tion is non-specific, LF is a potential imported infection 
in travelers from endemic countries, even though the 
incidence is low, with about 27 cases reported so far [16, 
17, 20–24]. The last two cases were reported from the 
US in 2014 and 2015 [23, 24]. Of 24 cases with reported 
data, almost all have worked in an endemic area for a 
prolonged time, with a third as HCW’s, and five as aid-
workers or peace-keepers. Seven of these died [22]. Some 
of the patients were medically evacuated from Africa, but 
others travelled by themselves, sometimes after disease 
presentation [17, 21].
Pathogenesis
LASV has a broad cell tropism, mostly using a cytoskel-
eton associated peptide, α-dystroglycan, as its recep-
tor. After infection the virus proliferates mainly in 
macrophages, dendritic and endothelial cells. The infec-
tion does not lead to lytic damage, and pathogenesis is 
related to immune suppression, uninhibited viral prolif-
eration and host responses. LASV inhibits host immune 
response in various ways. It bypasses the usual route of 
endosomal trafficking, crucial for innate immunity rec-
ognition. The viral NP directly suppresses interferon pro-
duction, and infected immune cells do not secrete other 
pro-inflammatory cytokines such as TNF-α, IL-6, and 
IL-1β. Therefore, LF does not manifest with a “cytokine 
storm” as other hemorrhagic viral fevers [13, 25].
The most important pathological change is an increase 
in capillary permeability, with development of edema and 
hypovolemic shock. Other changes include hepatitis with 
hepatic necrosis, and necrosis of the spleen and adrenals 
[13, 25].
The immune response to LASV is not completely 
understood. Cellular immunity is most important, with 
strong T cell responses in survivors [10]. Antibody 
responses are probably less important, and although spe-
cific antibodies are produced early in the disease, neutral-
izing antibodies appear only after weeks or months with 
low titers and avidity [11].
Clinical manifestation
The incubation period is usually 7–10  days, with a 
reported range of 3–21 days [11, 13, 15, 16, 18]. Twenty 
percent of cases have a severe disease, requiring hos-
pitalization, while 80  % have a mild or asymptomatic 
infection. The general case fatality rate is estimated as 
1–2 %. The mortality rate of hospitalized cases in Africa 
is 15–20 % [13], with reports of up to 50 % in some out-
breaks [26].
The disease begins gradually with a nonspecific flu-like 
illness, including fever and malaise. After 1–3  days, the 
patients report headache, throat pain, myalgia, abdomi-
nal pain, a retrosternal chest pain, cough, diarrhea, and 
vomiting. Physical examination might reveal hypoten-
sion, exhudative pharyngitis, lymphadenopathy, con-
junctivitis, and a maculopapular rash. Severe LF usually 
manifests in the second week with hypovolemic shock, 
facial edema, pulmonary edema, pleural effusion, ascites, 
renal failure, and neurological signs such as confusion 
and seizures. Hemorrhage is found in 17 % of cases only, 
is limited to mild mucosal bleeding, and does not signifi-
cantly contribute to shock. Survivors show improvement 
within 8–10  days, while fatal cases progress to coma, 
shock and death during the third week [10, 11, 13, 18]. 
Risk factors for death include age of <18 years or elderly, 
neurological involvement, pharyngitis, vomiting, aspar-
tate transaminase (AST) level above 110 IU, hemorrhagic 
signs and a plasma viral load of more than 103.6 TCID50 
(50 % tissue culture infective dose) [10, 11, 13, 18].
Laboratory findings include increase in transami-
nases, proteinuria, leukopenia, anemia and mild 
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thrombocytopenia, with a significant disorder of platelet 
function. Coagulation studies are usually normal [27].
The clinical presentation of LF is very similar to other 
common and endemic African diseases, such as malaria, 
typhoid fever, rickettsial infections and influenza, com-
plicating the differential diagnosis of returning travelers. 
Travelers with mild infections might be diagnosed if cli-
nicians would be aware of disease activity in the origin 
country, and therefore updates of the activity of LF and 
other contagious infections are important for clinicians 
in Israel and other countries. Symptoms that were found 
to be predictive of LF are fever, retrosternal chest pain, 
pharyngitis and proteinuria [18], with the first three pre-
dicting LF diagnosis with a positive predictive value of 
81 % [28].
Various complications were reported, including peri-
carditis, arrhythmia, pancytopenia and renal failure. 
Central nervous system involvement is typical, with 
development of meningitis, encephalitis, encephalopa-
thy, and cerebellar ataxia. Virus was isolated from CSF 
in some cases [29]. Sensorineural hearing loss (SNHL) 
is very typical and common, reported in 13.5 % of acute 
cases, and predicting worse outcome. Its presence during 
illness or recrudescence is suggestive of LF. After recov-
ery, a third of patients will have SNHL, irreversible in 
two-thirds of them [30, 31]. Severe abdominal pain with 
peritoneal signs was reported, with many cases operated 
for suspected surgical and gynecological emergencies. 
Some of these cases led to surgical staff infection [32]. 
LF tends to be more severe during pregnancy, mainly in 
its late stages, with fatality rates of up to 50 % and fetal 
loss in 75–100 % of cases [13, 26]. Uterine evacuation can 
lead to dramatic improvement [18, 33].
Diagnosis
The most useful way for diagnosis is polymerase chain 
reaction (PCR) from blood. Sensitivity was reported 
as 79 % on the first day of hospitalization, increasing to 
100 % on the third day [11, 13, 18]. Genetic strain vari-
ation might rarely lead to false negative results [34], and 
laboratory contamination to false positive ones [35]. 
Various serological tests are being used, including direct 
NP antigen testing and specific IgG and IgM antibod-
ies against NP and GP. A mixed NP and IgM ELISA has 
a sensitivity and specificity of 88 and 90  %, respectively 
[18]. IgM can persist for months and years, and IgG for 
decades [36]. Cross reactions with LCMV exist [17]. 
Clinical samples from LF patients are a significant haz-
ard to laboratory personnel, with percutaneous inocula-
tions and contact with mucosal surfaces as the main risk 
factors for infection. This mandates high level of safety 
in collection and processing of samples, including use of 
personal protective equipment by laboratory personnel. 
Isolation of LASV in cell cultures and in animals is the 
gold standard, but necessitates extreme biosafety condi-
tions (Biosafety level 4) [37].
Treatment
Similar to other severe hemorrhagic fevers, supportive 
treatment is the cornerstone of clinical management of 
LF. The main goal is volume resuscitation, accounting for 
third spacing, diarrhea and vomiting, while avoiding vol-
ume overload due to the risk of pulmonary edema. Other 
goals are electrolyte balance and respiratory support.
Convalescent plasma, although beneficial in some ani-
mal experiments, has failed clinical studies, probably due 
to lack of neutralizing antibodies [38, 39]. Ribavirin, a 
broad spectrum guanosine analogue antiviral, possesses 
good activity against LASV. Intravenous treatment in 
standard doses leads to plasma concentrations that are 
significantly higher than the minimal inhibitory con-
centration (MIC), while oral treatment, limited by side 
effects and a 50 % bioavailability, leads to low to border-
line concentrations, doubtfully inhibiting LASV in  vivo 
[16]. Animal studies with parenteral ribavirin treatment 
proved it to be protective, with survival benefit in non-
human primates, even when treatment was begun 5 days 
after infection [16]. A controlled clinical trial performed 
in the 1980s by the CDC in Sierra Leone, assessed the 
benefit of intravenous and oral ribavirin [39]. The results 
of this single human trial are presented on Table 1. Riba-
virin treatment was significantly associated with survival. 
Benefit was even more significant in higher risk patients 
with high level viremia and increased liver function tests, 
and when within 6 days from symptom onset. Both oral 
and intravenous ribavirin were beneficial, with the latter 
showing a stronger effect in higher risk cases. The recom-
mended intravenous dosing is based on this pivotal study, 
with a 2.4 g loading dose, followed by 1 g every 6 h for 
10 days, for average weight adults.
Ribavirin’s main adverse effect is dose dependent hemol-
ysis, appearing in ~20  % of patients, usually resulting in 
modest decrease in hematocrit [39]. Oral treatment is 
associated with many more adverse effects, including nau-
sea, vomiting, diarrhea, metal taste, dry mouth, myalgia, 
fatigue, headache, jaundice, rash, tachycardia, thrombocy-
tosis, increased lipase levels, mood changes and insomnia. 
However, no mortality was reported after ribavirin treat-
ment [16]. Ribavirin is teratogenic and embryotoxic in 
rodents, and is contraindicated during pregnancy and lac-
tation, although due to the grave prognosis of LF in preg-
nant women, the risk should be weighed against its benefit.
Various experimental treatments were evaluated for LV, 
including antivirals, molecules targeting host cells, and 
immunomodulators. None is currently clinically proven 
or approved for treatment [40].
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Prevention
The main preventive step in endemic areas is rodent 
control in and around dwellings, avoiding contact with 
rats and consumption of them [13]. For foreign workers 
and diplomats living in endemic areas during outbreaks, 
the main preventive strategies are to avoid contact with 
rodents, with ill persons and with local health services, 
if proper infection control practices are not well main-
tained. No vaccine is currently available against LASV. 
Effective vaccine candidates should produce long lasting 
strong cellular immune responses. Various vaccines were 
tested in animals [38], including live virus vaccine with 
non-pathogenic AV such as Mopeia virus, and recombi-
nant viral vectors such as vaccinia virus, vesicular stoma-
titis virus and yellow fever virus, carrying LASV antigens.
When dealing with imported cases in the western 
world, the main focus for prevention is hospital infec-
tion control, with extensive history of LF nosocomial 
outbreaks in Africa. The main risk is from contami-
nated needles or direct contact of patient blood or secre-
tions with mucous membranes or injured skin. These 
outbreaks involved institutions with very low level of 
infection control, lack of protective equipment (gloves, 
masks), needle re-use, and surgery under poor hygienic 
conditions [10, 41]. Indeed, in African hospitals, where 
proper barrier nursing was practiced, HCW’s did not 
have a higher seroprevalence for LASV than the neigh-
boring rural community [42]. In addition, only one sus-
pected secondary infection of a HCW was reported from 
cases treated outside Africa, with a physician exhibiting 
LASV-IgG without symptoms after inserting an intrave-
nous catheter without gloves into a severe LF case [17]. 
Airborne transmission of LASV is not proven. Only 
one report from Nigeria in 1970, suggested airborne 
transmission within a hospital, with secondary cases that 
did not have direct or close contact with the original case 
[43]. The virus is stable in aerosols under conditions of 
low temperature and humidity, and successfully infects 
animals via the airborne route [11, 44]. Transmission of 
LASV between distanced animal cages was reported, too 
[45]. Due to these factors, LASV is categorized as a high 
risk (Biosafety level 4) agent for laboratory work [37], 
but the recommendations for hospital infection control 
are paradoxical. Formal international guidelines from 
the WHO include only contact and droplet-based pre-
cautions, with use of gloves, long sleeved coats, surgical 
mask and a face/eye shield [14]. Others recommend neg-
ative-pressure isolation rooms [11], or specialized high-
level isolation units, using exceptional infection control 
practices, in order to prevent risks to HCW’s [46, 47]. 
In fatal cases, special care of patient’s remains should be 
practiced in order to prevent exposure to body fluids or 
tissues. This might include incineration or closed coffins, 
and avoiding direct contact with the body [15].
Post exposure prophylaxis (PEP) with ribavirin after 
contact with a LF patient can be offered. Animal studies 
have shown good protection up to 5 days post-exposure. 
No clinical study was done to evaluate PEP efficacy. Most 
of the data is anecdotal, and actually the oral regimens 
that were used are expected to produce lower ribavirin 
plasma levels than those proven effective in animal stud-
ies by an order of magnitude [16]. Since oral ribavirin 
treatment is associated with a high rate of adverse effects, 
PEP is recommended only to high risk contacts: con-
taminated needle accidents, direct contact of body fluids 
with mucous membranes or injured skin, participation 
in emergency medical treatment without proper protec-
tive equipment or staying with the patient in an enclosed 
space for many hours. Consideration can be given to the 
patient’s level of contagiousness, reflected by the severity 
of illness and presence of vomiting, diarrhea and bleed-
ing. A dosing protocol was suggested by Bausch et al. [16] 
with a 2.4 g loading dose, followed by 1 g every 6 h for 
6 days, and 0.5 g every 6 h for 4 more days.
Conclusions
Physicians in Israel and other countries outside Africa 
have to be alert to the risk of imported endemic disease, 
such as LF. The ever-growing global travel is increasing 
the risk for such an episode. In addition, LASV can serve 
as an agent of bioterrorism, leading to a local outbreak 
in non-endemic areas [48]. It is categorized as a category 
A threat priority agent by the US National Institute of 
Allergy and Infectious Diseases (NIAID) [49]. Military 
physicians might be especially involved if military per-
sonnel are used for management of bioterrorism inci-
dents or if soldiers are deployed to endemic regions.
Table 1 Mortality rate in LF patients treated with ribavirin 
[39]
AST aspartate transaminase, TCID50 50 % Tissue culture inhibitory dose
* Significantly lower than mortality with no treatment














AST >150 IU All cases 55 14* 19*
Within 6 days 61 20* 5*




All cases 76 30* 32*
Within 6 days 75 20* 9*




All cases 28 7* 9*
Page 5 of 6Brosh‑Nissimov  Disaster and Mil Med  (2016) 2:8 
Although usually non-fatal and not highly contagious, 
some patients develop a severe infection and lead to 
nosocomial outbreaks. Clinicians should suspect LF in 
travelers from an endemic area with a febrile illness, after 
ruling out common travel-related infections. Unlike most 
other viral hemorrhagic fevers, LF can be treated with 
ribavirin, if diagnosed early enough. Simple good infec-
tion control principles will prevent most of the risk for 
nosocomial transmission. The use of airborne precau-
tions, probably unnecessary for most LF patients, might 
be considered in severe cases, and while conducting aer-
osol-generating procedures.
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